这篇文章涉嫌多处图片重复使用被撤稿

图片重复使用是常见的撤稿原因之一。现在下面这篇文章就是因为图片重复使用被撤稿,文章发表在Journal of Ovarian Research上,文章题目:Retraction Note: The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer。

官方撤稿原因:

The Editors-in-Chief have retracted this article [1]. Concerns were raised with Figures 2 and 3, specifically:

Figure 2E: the panels for Group-2 and Group-3 appear to partially overlap.

Figure 2E: the panels for nab-P and AP appear to partially overlap.

Figure 3E: the panels for Bax/Group-1 and Bax/Group-3 appear to partially overlap.

Figure 3E: the panels for Bax/Group-2 and bcl-2/Control group appear to partially overlap.

Figure 3E: the panel for CD31/Group-1 appears to partially overlap with the panels for CD31/Group-3 and MMP-2/Group-2.

Figure 3E: the panel for CD31/Group-3 appears to partially overlap with the panels for MMP-2/Group-1 and MMP-2/Group-2.

Figure 3E: the panel for CD31/Group-3 appears to partially overlap with the panel for MMP-2/Group-1.

Figure 3E the panels for MMP-2/Group-1 and MMP-2/Group-2 appear to partially overlap.

The Editors-in-Chief have therefore concluded that the data reported in this article are unreliable. The authors have not responded to any correspondence regarding this retraction。

参考文章:Zhao H, Li R, Wang X, et al. The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer. J Ovarian Res. 2020;13:113. doi:

10.1186/s13048-020-00719-3.

推荐阅读更多精彩内容